MOUNTAIN VIEW, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Pharsight Corporation , a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, today announced that Kevin Dykstra, Ph.D., vice president and lead scientist, Strategic Consulting Services, has been invited to speak to members of the pharmaceutical and biotechnology industries attending the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, to be held in San Diego, California at the San Diego Convention Center from November 11-15, 2007.
As part of an AAPS pre-conference workshop, organized and delivered by experts from industry and academia, Dr. Dykstra's presentation will discuss the role of quantitative pharmacology as a data-driven framework to enable rational decision making in drug development. Dr. Dykstra will present a model-based case study that features development of an integrated metric, the clinical utility index, or CUI, to assess the competing considerations affecting a treatment's clinical utility. Dr. Dykstra's presentation, entitled "Integrated Modeling and Simulation to Evaluate the Viability of a Proposed Drug Development Program", will take place on November 10, 2007 at 1:15 pm.
The AAPS workshop will feature applied examples illustrating the impact of modeling and simulation on critical drug development decisions, and will include a regulatory perspective from the Food and Drug Administration on use of model-based drug development in the drug approval process. The session will also provide a forum for scientific discussion and collaborative exchange on opportunities and challenges associated with the implementation of quantitative pharmacology. Additional information can be found at http://www.aapspharmaceutica.com.
"Model-based drug development is a valuable set of interdisciplinary approaches that improves the confidence level in the drug development decision-making process," said Shawn O'Connor, president, CEO, and chairman of Pharsight. "A CUI quantifies factors like a product's efficacy, safety, cost, and contribution to quality of life and makes trade-offs transparent to decision makers. Linking a CUI to predictive models of drug action and effect can support critical program decisions, including whether reformulating an existing drug provides sufficient patient benefit and distinction among other competing products to warrant further investment. We look forward to participating in the AAPS workshop, sharing quantitative pharmacology methods with workshop attendees and exchanging information with industry colleagues on the strategic use of modeling and simulation."
About Pharsight Corporation
Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. Pharsight's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.
Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.
Registered Trademarks and Trademarks
Pharsight is a registered trademark of Pharsight Corporation. All other brand or product names mentioned in this documentation are trademarks or registered trade marks of their respective companies or organizations.
CONTACT: investors, Douglas Sherk, +1-415-896-6820, or Jennifer
Beugelmans, +1-646-201-5447, or media, Jen Saunders, +1-646-201-5431, all
of EVC Group, for Pharsight Corporation
Web site: http://www.pharsight.com/
http://www.aapspharmaceutica.com/
